Using healthy donors as well as MS patients PBMCs, it was shown that in vitro treatment with IFN-β enhanced PD-L1 expression on monocytes and DCs, inhibited antigen-specific CD4+ T-cell activation, and increased Treg numbers. This evidence concerns the gene IFNB1 and myeloid sarcoma.